biocon declares its q3 report fy19| chartbusters| january 25, 2019
Published 5 years ago • 272 plays • Length 7:17Download video MP4
Download video MP3
Similar videos
-
2:49
r&d spending: our pipeline is our 'lifeline,' says indian biotech firm
-
5:08
palantir has momentum, 'valuation is the concern', says jefferies' brent thill
-
0:57
#earningsminute: biocon puts up a strong show in q3
-
10:00
top 10 stocks of the day| bazaar morning call| january 25, 2019
-
17:20
biocon's q2 results decoded. exclusive interview with biocon's management on earnings & plans ahead
-
2:12
biocon q3 estimates || revenue decline of 1.6% is expected || cnbc tv18
-
59:51
$mrk merck q3 2024 earnings conference call
-
5:41
is merck stock priced too high?
-
10:27
we have a blueprint for what wall street thinks a harris presidency will mean, says jim cramer
-
22:30
nirmal bang's vishal manchanda on biocon | trading hour | cnbc tv18
-
9:10
cnk q3 2024 earnings recap - cinemark posts record q3 revenue!
-
1:44
biocon's q2 revenue rises while margin falls; cipla's goa facility gets vai status from us fda
-
8:31
biosimilar growth is offsetting decline in syngene & generics: biocon | cnbc tv18
-
6:04
merck ceo robert davis on q3 results: our portfolio sets us up for a good finish to the year
-
6:59
servicenow ceo on q3 earnings beat: digital transformation has turned into business transformation
-
1:56
cnbc-tv18 explains: what the current government can do
-
4:28
ceo of india's biocon discusses first-quarter results
-
0:51
trastuzumab's approval and marketing in the us offers huge potential for the company: biocon
-
1:25
what is the street expecting from biocon & syngene this q2?
-
9:09
confident that issues at malaysian plant will be behind once it is inspected: biocon biologics
-
14:39
first on cnbc-tv18 | biocon cmd: "biologics business saw a robust jump in sales"
-
2:54
biocon sells 5.4% stake in syngene to fund viatris biologics biz acquisition | halftime report